ClinicalTrials.gg
RecruitingNCT07483710SIMSUpdated Jul 10, 2026

Association Between Muscle L3 CT Scan Muscle Derived Parameters of Muscle Function Upon Intensive Care Unit Admission and 3 Months Mortality After ICU Discharge for Patients Admitted for Septic Shock. The SIMS Study

An interventional study of Evaluation of muscle dysfunction in intensive care units for septic schock patients in Septic Shock, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Recruiting at 4 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
196
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 184 studies in Shock, Septic with a site in France — 45 open to participants now, 50 under way, 7 of them phase 3. Shock, Septic · France.

Planned enrollment
38th of 105
196 · median 120
Started
2026
with 16 others
No phase
52 of 184
14 open now
Primary completion
2030-05
later than 47 of 49 live
Registered
177th of 184
by date

Among the 184 studies in Shock, Septic with a site in France, this one is the 38th largest by planned enrollment of the 105 interventional ones that give a count, is one of 17 that started in 2026, is one of 52 with no phase, reaches primary completion later than 47 of the 49 other live ones, and was the 177th registered.

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

45 of the 184 studies in Shock, Septic with a site in France are open now. Recruiting first, the newest first:

39 more — sign in →

All 45 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies in Shock, Septic with a site in France, or all of them as a file.
02

Study summary

Muscle dysfunction in intensive care units is associated with significant morbidity and mortality. During septic shock, there is an increased catabolism and systemic inflammation resulting in quantitative and qualitative muscle impairment. In the intensive care setting, quantitative and qualitative assessment of muscle function is challenging due to critical care environments (general anesthesia, altered consciousness, etc.). CT scan measurement at the 3rd lumbar level has been proposed to evaluate muscle function. Recent retrospective studies have highlighted increased mortality among patients with muscle mass impairment and/or decreased muscle density.

Read the detailed description

To date, no prospective study has assessed the prognostic value of CT scan measurements of muscle function upon admission to intensive care units for patients treated for septic shock. That is the aim of this project.

03

Conditions studied

  • Septic Shock

Browse trials for

Keywords

  • septic shock
  • CT Scan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients hospitalized in intensive care for septic shock defined by the presence of a documented or suspected infection, plasma lactate >2 mmol/L, and an increase in SOFA score of more than 2 points from baseline (Singer et al., 2016)

  • Patients who underwent a non-contrast CT scan within 48 hours prior to admission and up to 24 hours after admission to intensive care
  • Patients affiliated with or eligible for social security

Exclusion criteria

Exclusion Criteria:

  • Patients with a neuromuscular disease prior to admission to intensive care.
  • Pregnant women
  • Patients under guardianship and/or conservatorship
  • Refusal of consent.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
196 participants (estimated)

Study arms

  • Other
    Septic shock patients

    Evaluation of muscle dysfunction in intensive care units for septic shock patients

    Other: Evaluation of muscle dysfunction in intensive care units for septic schock patients

Interventions

  • OtherEvaluation of muscle dysfunction in intensive care units for septic schock patients

    Correlation between muscle L3 CT scan muscle derived parameters of muscle function upon intensive care unit admission and 3 months mortality after ICU discharge for patients admitted for septic shock

06

What researchers measure

Primary outcomes

  1. vital status

    alive or dead

    Time frame: 90 days

  2. Total muscle mass measured at L3 (cm²/m² )

    Total muscle mass measured at L3 by CT scan, normalized by patient height (Skeletal Muscle Index), in cm²/m² upon admission to the ICU (Correlation between three L3 CT scan parameters of muscle function upon admission to the intensive care unit and the risk of mortality at 3 months after ICU discharge in septic shock patients).

    Time frame: at inclusion

  3. Total muscle density measured at L3 ( Hounsfield Unit)

    \- Total muscle density measured at L3 by CT scan (Skeletal Muscle Density) in HU upon admission to the ICU (Correlation between three L3 CT scan parameters of muscle function upon admission to the intensive care unit and the risk of mortality at 3 months after ICU discharge in septic shock patients).

    Time frame: at inclusion

  4. Total fat excretion fraction measured at L3 (%)

    Total fat excretion fraction measured at L3 (Fat Fraction) by CT scan upon admission to the ICU (Correlation between three L3 CT scan parameters of muscle function upon admission to the intensive care unit and the risk of mortality at 3 months after ICU discharge in septic shock patients).

    Time frame: at inclusion

Secondary outcomes

  1. SOFA (Sequential Organ Failure Assessment) severity score

    minimum=0, maximum=3 (Worse score)

    Time frame: at inclusion, 10 days.

  2. Kinetics of changes in muscle assessment

    To assess the kinetics of changes in muscle scan parameters and muscle function.

    Time frame: Day 1, 10, 90

  3. Total fat excretion fraction measured at L3 (%)

    Evolution of the total fat excretion fraction measured at L3 (Fat Fraction) by CT scan at inclusion, 10 days and 90 days.

    Time frame: at inclusion, 10 days, 90 days

  4. Total muscle density measured at L3 ( Hounsfield Unit)

    Evolution of total muscle density measured at L3 by CT scan (Skeletal Muscle Density) in HU upon inclusion, 10 days, 90 days

    Time frame: at inclusion, 10 days, 90 days

  5. Total muscle mass measured at L3 (cm²/m² )

    Evolution of the total muscle mass measured at L3 by CT scan, normalized by patient height (Skeletal Muscle Index), in cm²/m² upon inclusion, 10 days, 90 days.

    Time frame: at inclusion, 10 days, 90 days

  6. MRC score (Medical Research Council)

    Minimum=0 (worse score), Maximum=5

    Time frame: at discharge from intensive care, 90 days

  7. Handgrip test (Kg)

    Time frame: at discharge from intensive care, 90 days

07

Study locations

1 of 4 sites recruiting
  • Hospices Civils de Lyon
    Lyon, 69000, France
    Not yet recruiting
  • AP HM, Hôpital La Timone
    Marseille, 13385, France
    Not yet recruiting
    • Pierre SIMEONE, MD · Contactpierre.simeone@ap-hm.fr · (0)4 91 38 00 00
    • Bénédicte GRIGORESCO, MD · Sub investigator
  • Clinique Mutualiste
    Saint-Etienne, 42000, France
    Not yet recruiting
  • Centre Hospitalier Universitaire de Saint-Etienne
    Saint-Etienne, 42055, France
    Recruiting
    • NORY ELHADJENE, MD · Contactnory.elhadjene@gmail.com · (0)4.77.82.97.43
    • Jérôme MOREL, MD PhD · Sub investigator
    • Léonard FEASSON, MD PhD · Sub investigator
    • Pierre CROISILLE, MD PhD · Sub investigator
    • Rémi GRANGE, MD · Sub investigator
    • Sylvain GRANGE, MD · Sub investigator
    • Nicolas MAILLARD, MD PhD · Sub investigator
    • Guillaume THIERRY, MD PhD · Sub investigator
    • Sophie PERINEL-RAGEY, MD PhD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for May 2030, 49 months after the start.

Of 165 non-industry interventional studies with no phase under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 49 months is above that.

Counting every sponsor, half of 173 studies reached it within 25 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2026
First posted
Mar 19, 2026
StartActual
Mar 19, 2026
Primary completionEst.
May 1, 2030
CompletionEst.
May 1, 2030
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07483710
Responsible party
Sponsor
First posted
Mar 19, 2026
Start date
Mar 19, 2026
Primary completion
May 1, 2030 (estimated)
Completion
May 1, 2030 (estimated)
Last update
Jul 10, 2026

Study contacts

Nory Elhadjene, MD
Contact
nory.elhadjene@gmail.com
(0)4.77.82.97.43 ext. +33
Nory Elhadjene, MD
principal investigator · Centre Hospitalier Universitaire de Saint Etienne

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion